What is Intellia Therapeutics Book Value per Share?
Intellia Therapeutics's book value per share for the quarter that ended in Mar. 2024 was $10.76.
During the past 12 months, Intellia Therapeutics's average Book Value Per Share Growth Rate was -20.40% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 12.40% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 19.80% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the book value growth rate using book value per share data.
During the past 10 years, the highest 3-Year average Book Value Per Share Growth Rate of Intellia Therapeutics was 38.20% per year. The lowest was -2.60% per year. And the median was 12.40% per year.
During the past 10 years, the highest P/B Ratio of Intellia Therapeutics was 24.41. The lowest was 1.88. And the median was 3.20.
Good Sign:
Intellia Therapeutics Inc stock PB Ratio (=1.99) is close to 10-year low of 1.88
Intellia Therapeutics Book Value per Share Historical Data
The historical data trend for Intellia Therapeutics's Book Value per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Intellia Therapeutics's Book Value per Share
For the Biotechnology subindustry, Intellia Therapeutics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Intellia Therapeutics's PB Ratio Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Intellia Therapeutics's PB Ratio distribution charts can be found below:
* The bar in red indicates where Intellia Therapeutics's PB Ratio falls into.
Intellia Therapeutics Book Value per Share Calculation
Intellia Therapeutics's Book Value Per Share for the fiscal year that ended in Dec. 2023 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Book value may include intangible items which may come from the company's past acquisitions. Book value less intangibles is called Tangible Book.
Intellia Therapeutics (LTS:0JBU) Book Value per Share Explanation
Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.
For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.
Intellia Therapeutics Book Value per Share Related Terms
Thank you for viewing the detailed overview of Intellia Therapeutics's Book Value per Share provided by GuruFocus.com. Please click on the following links to see related term pages.
Intellia Therapeutics (LTS:0JBU) Business Description
Intellia Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
LTS:0JBU has been successfully added to your 